Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oseltamivir (Tamiflu) Clear all
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 4, 2026, 8:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alcohol Inhibits Drug Metabolism by Carboxylesterases

NCT01708369
View directory record Official record
Conditions
Drug Interactions
Interventions
Placebo, Ethanol, Oseltamivir, Aspirin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 4, 2026, 8:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

NCT05170009
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo, Oseltamivir
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

NCT04536415
View directory record Official record
Conditions
Bioequivalence
Interventions
Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
Drug
Lead sponsor
Austarpharma, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.

NCT00304434
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Probenecid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 4, 2026, 8:15 AM EDT
Terminated Phase 4 Interventional Results available

Test-and-treat for Influenza in Homeless Shelters

NCT04141917
View directory record Official record
Conditions
Influenza, Respiratory Viral Infection
Interventions
Point-of-care molecular testing and treatment of influenza
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
3 Months and older
Enrollment
1,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Burien, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 4, 2026, 8:15 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

NCT01032837
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
100
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

NCT01248715
View directory record Official record
Conditions
Influenza, Pneumonia
Interventions
oseltamivir
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
1,107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

NCT00416962
View directory record Official record
Conditions
Healthy
Interventions
amantadine hydrochloride, oseltamivir phosphate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 30, 2007 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139
View directory record Official record
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

NCT01050257
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir IV, Oseltamivir Oral
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 4, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

NCT02469298
View directory record Official record
Conditions
Virus Diseases
Interventions
GSK1325756 (Danirixin), Placebo To Match GSK1325756, Oseltamivir Phosphate, Placebo To Match Oseltamivir Phosphate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

NCT01715909
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

NCT02609399
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Peramivir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

NCT00555893
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
1 Year to 79 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 4, 2026, 8:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Pharmacology of Tamiflu in Pregnancy

NCT01203527
View directory record Official record
Conditions
H1N1 Influenza Treatment During Pregnancy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 45 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

NCT00412555
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir [Tamiflu]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
West Palm Beach, Florida • Pittsburgh, Pennsylvania • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 4, 2026, 8:15 AM EDT
Completed No phase listed Observational

Chart Review of Antivirals for Influenza in Infants

NCT00311701
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 11 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Birmingham, Alabama • Pulaski, Arkansas • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 4, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

NCT01048879
View directory record Official record
Conditions
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions
pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 4, 2026, 8:15 AM EDT